No Data
No Data
Calidi Biotherapeutics Prices $7.5M Secondary Offering
Calidi Biotherapeutics Shares Are Trading Higher After the Company Announced It Presented Data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting.
Calidi Biotherapeutics Reveals Promising Virotherapy Data
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
Calidi Biotherapeutics: Innovative Cancer Treatment With Promising Clinical Results but Financial Challenges
NYSE American Net Change Percentage Gainers & Losers
Unlock the Full List